ArticlePLoS neglected tropical diseases2026
Surgical management of cystic echinococcosis-A 20-year case series and outcome analysis.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic echinococcosis (CE) is a parasitic zoonosis, caused by the larval stage of Echinococcus granulosus, typically forming cysts in the liver. If untreated, CE can be life-threatening. Albendazole remains the standard medical therapy, but surgical intervention is indicated in selected cases. METHODOLOGY/PRINCIPAL
findingsWe conducted a retrospective, multicenter outcome analysis in Switzerland of surgically treated cystic echinococcosis from 2004 to 2024. Patients with CE stages 1-3b undergoing pericystectomy, endocystectomy, or non-resectional procedures were included. The primary objective was to evaluate the safety and efficacy of surgical treatment. Data on patient demographics, disease characteristics, and perioperative morbidity and mortality, as well as recurrence rates stratified by surgical technique were analyzed. Among 37 patients, 83.8% (n = 31) had hepatic involvement, 8.1% (n = 3) pulmonary, 5.4% (n = 2) intestinal, and 2.7% (n = 1) psoas involvement. All patients received adjuvant albendazole therapy for a median duration of 4 months (3-204 months). Across 39 surgical interventions, 82.1% of procedures (n = 32) had one or two cysts (range 1-8), with a median cyst size of 8 cm (2.1-19 cm). The median follow-up was 93 months (12-230 months). The overall recurrence rate at the procedure level was 7.7% (n = 3), occurring after three different procedures (endocystectomy, cyst aspiration and fenestration, and open PAIR with cyst deroofing). No recurrences were observed after pericystectomy (0/32 procedures). The 90-day postoperative mortality rate was 0%.
conclusionsIn this cohort, surgical treatment, particularly pericystectomy, was associated with low recurrence and no 90-day mortality. These findings support surgery as an important component of multimodal management in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.